113年學術活動 – 2024/08/24

近年液態切片(liquid biopsy)次世代定序(next generation sequencing, NGS)基因檢測在癌症治療追蹤扮演重要的角色，它的優勢是透過抽血，以非侵入的方式檢測循環腫瘤DNA(Circulating Tumor DNA, ctDNA)，可用以監測治療效果、癌症復發和突變，提供即時的病情動態資訊，提升癌症管理的精確性和患者預後。
本研習會將介紹液態切片NGS基因檢測的原理與方法，技術上的突破與發展，以及目前應用在癌症追蹤的最新趨勢，並將介紹微小殘留病(minimal residual disease, MRD)液態切片NGS基因檢測於癌症治療後監測之應用。微小殘留病(MRD)液態切片的技術能早期發現微小病灶，評估治療效果及復發風險，有助於個人化醫療的規劃實施。
透過本次研習會，我們期望促進液態切片NGS基因檢測技術新知交流，助益醫療專業人員了解相關技術在臨床實踐的應用及潛力，並推動相關研究發展。歡迎有興趣的人士，踴躍報名參加！

Introduction:
In recent years, liquid biopsy next-generation sequencing (NGS) gene testing has played an important role in cancer treatment monitoring. Its advantage lies in detecting circulating tumor DNA (ctDNA) through blood samples, offering a non-invasive method to monitor treatment effectiveness, cancer recurrence, and mutations. This provides real-time information on disease dynamics, enhancing the accuracy of cancer management and patient prognosis.
This workshop will introduce the principles and methods of liquid biopsy NGS gene testing, its breakthroughs and developments, and the latest trends in its application for cancer monitoring. It will also cover the application of minimal residual disease (MRD) liquid biopsy NGS gene testing in post-cancer treatment monitoring. MRD liquid biopsy technology enables early detection of minimal disease, assessment of treatment efficacy, and evaluation of recurrence risk, aiding in the implementation of personalized medicine.
Through the exchange of knowledge on liquid biopsy NGS gene testing technology in this workshop, we aim to help medical professionals understand its clinical applications and potential, and to promote related research and development. We welcome your participation!